Response to Drug Scheduling as Institutional Design
Vol. 139 No. 7 Professors Matthew Lawrence and David Pozen’s Drug Scheduling as Institutional Design is an ambitious and welcome intervention in the long-running debate over U.S. drug policy. The authors reconceptualize...
Congress doesn’t do anything anymore. Despite Republican control of the House, the Senate, and the presidency, Congress seems to be fading into the background of the current political landscape. At the...
Vol. 139 No. 7 The Supreme Court promises that government action is illegitimate if it “lack[s] any purpose other than a ‘bare . . . desire to harm a politically unpopular group.’”...
On February 12, 2026, the Environmental Protection Agency promulgated a final rule rescinding its finding that greenhouse gases (GHGs) endanger public health and welfare....
The organizations that accredit colleges and universities by definition influence much of what institutions of higher education do and how they do it. For...
Vol. 139 No. 5 All legislative Powers herein granted shall be vested in a Congress of the United States . . . . — U.S. Const. art. I, § 1 Typically, when Congress...
Vol. 139 No. 4 The United States makes bad choices when it comes to psychoactive drugs. Under the Controlled Substances Act (CSA), U.S. drug law has simultaneously fueled mass incarceration, inhibited needed access, and enabled an opioid crisis.
President Trump is once again threatening to cut federal funding for “sanctuary jurisdictions” that fail to cooperate with his Administration’s forceful immigration policies. The...